JP2010065037A5 - - Google Patents

Info

Publication number
JP2010065037A5
JP2010065037A5 JP2009233816A JP2009233816A JP2010065037A5 JP 2010065037 A5 JP2010065037 A5 JP 2010065037A5 JP 2009233816 A JP2009233816 A JP 2009233816A JP 2009233816 A JP2009233816 A JP 2009233816A JP 2010065037 A5 JP2010065037 A5 JP 2010065037A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
apo
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009233816A
Other languages
Japanese (ja)
Other versions
JP2010065037A (en
Filing date
Publication date
Application filed filed Critical
Publication of JP2010065037A publication Critical patent/JP2010065037A/en
Publication of JP2010065037A5 publication Critical patent/JP2010065037A5/ja
Pending legal-status Critical Current

Links

Claims (1)

図１（配列番号１）の天然配列Ａｐｏ−２リガンドポリペプチド配列とは異なり、次の図１（配列番号１）の残基位置のアミノ酸置換：Ｓ９６Ｃ；Ｓ１０１Ｃ；Ｓ１１１Ｃ；Ｒ１７０Ｃ；Ｋ１７９Ｃのうち１又は複数を有するアミノ酸配列を含んでなる、単離されたＡｐｏ−２リガンド変異体ポリペプチド。   Unlike the native sequence Apo-2 ligand polypeptide sequence of FIG. 1 (SEQ ID NO: 1), the amino acid substitution at the residue position of the following FIG. 1 (SEQ ID NO: 1): S96C; S101C; S111C; R170C; 1 of K179C Or an isolated Apo-2 ligand variant polypeptide comprising an amino acid sequence having a plurality.
JP2009233816A 2002-06-24 2009-10-07 Apo-2 ligand/trail variant and use thereof Pending JP2010065037A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39105002P 2002-06-24 2002-06-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004516142A Division JP4574350B2 (en) 2002-06-24 2003-06-23 APO-2 ligand / TRAIL variant and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2010065037A JP2010065037A (en) 2010-03-25
JP2010065037A5 true JP2010065037A5 (en) 2010-12-09

Family

ID=30000661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004516142A Expired - Lifetime JP4574350B2 (en) 2002-06-24 2003-06-23 APO-2 ligand / TRAIL variant and methods of use thereof
JP2009233816A Pending JP2010065037A (en) 2002-06-24 2009-10-07 Apo-2 ligand/trail variant and use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004516142A Expired - Lifetime JP4574350B2 (en) 2002-06-24 2003-06-23 APO-2 ligand / TRAIL variant and methods of use thereof

Country Status (7)

Country Link
US (4) US20060141561A1 (en)
EP (2) EP2500032A1 (en)
JP (2) JP4574350B2 (en)
AU (2) AU2003247609A1 (en)
CA (1) CA2489348A1 (en)
IL (1) IL165777A0 (en)
WO (1) WO2004001009A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1501866A4 (en) * 2001-10-02 2006-02-08 Genentech Inc Apo-2 ligand variants and uses thereof
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
JP2007530588A (en) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド Receptor coupling agent and therapeutic use thereof
EP1791864A2 (en) * 2004-09-08 2007-06-06 Genentech, Inc. Methods of using death receptor ligands and cd20 antibodies
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
KR100886783B1 (en) 2006-06-12 2009-03-04 성균관대학교산학협력단 N-terminal modified PEG-TRAIL, method for preparing and uses thereof
WO2008088582A2 (en) * 2006-08-04 2008-07-24 Mayo Foundation For Medical Education And Research Methods and materials related to trail isoforms
RU2472530C2 (en) 2007-09-24 2013-01-20 Бар-Илан Юниверсити Magnetic metal oxide coated polymer nanoparticles and use thereof
AU2008319298B2 (en) * 2007-10-31 2014-07-31 Medimmune, Llc Protein scaffolds
WO2011079293A1 (en) * 2009-12-23 2011-06-30 Ambrx, Inc Tumor necrosis factor-related apoptosis inducing ligand polypeptides and their uses
CN102906112B (en) 2010-04-13 2016-12-07 米迪缪尼有限公司 TRAIL R2-specificity polymer support
RS60828B1 (en) 2011-10-11 2020-10-30 Viela Bio Inc Cd40l-specific tn3-derived scaffolds and methods of use thereof
MX350202B (en) 2012-03-28 2017-08-30 Amgen Inc Dr5 receptor agonist combinations.
JP6463359B2 (en) 2013-08-12 2019-01-30 ジェネンテック， インコーポレイテッド Compositions and methods for treating complement related conditions
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
BR112016025312A2 (en) 2014-05-01 2017-10-17 Genentech Inc antibody variants, anti-d-factor antibody, pharmaceutical formulation, dispensing device, use of the formulation and a composition, composition and method of treating a disorder
KR20150133576A (en) * 2014-05-20 2015-11-30 삼성전자주식회사 Chemically modified targeting protein and use thereof
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
CN108289951A (en) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 Anti- factor D antibody and conjugate
JP6797203B2 (en) 2015-12-17 2020-12-09 ザ・ジョンズ・ホプキンス・ユニバーシティー Improvement of systemic sclerosis by death receptor agonist
CA3020339C (en) 2016-04-07 2022-05-03 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
IT201900024622A1 (en) * 2019-12-18 2021-06-18 Univ Degli Studi G Dannunzio Chieti Pescara INNOVATIVE PEGILATION OF THE KILLER TNF-APOPTOSIS INDUCED LIGAND (KILLER-TRAIL)

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
ES2032831T5 (en) 1986-08-19 2001-02-16 Genentech Inc DEVICE AND DISPERSION FOR INTRAPULMONARY SUPPLY OF POLYPEPTIDE AND CYTOKIN GROWTH FACTORS.
US5169770A (en) 1987-12-21 1992-12-08 The University Of Toledo Agrobacterium mediated transformation of germinating plant seeds
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DK168302B1 (en) 1989-06-29 1994-03-07 Danisco Method of introducing molecules, especially genetic material into plant cells
EP1132471A3 (en) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-binding proteins
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
JPH06500559A (en) 1990-08-17 1994-01-20 ジェネンテク，インコーポレイテッド Metal ion-mediated receptor binding of polypeptide hormones
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
AU1757092A (en) 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
EP0679095A1 (en) 1992-11-25 1995-11-02 Amgen Boulder Inc. Modified insulin-like growth factors
CA2160154A1 (en) 1993-04-07 1994-10-13 George N. Cox Methods of using insulin-like growth factor binding proteins
AU685187B2 (en) * 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
NZ311982A (en) 1995-06-29 1999-08-30 Immunex Corp Tnf related apoptosis inducing ligand (trail), a method for producing them and associated antibodies
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
PT1568772E (en) 1995-09-21 2010-04-14 Genentech Inc Human growth hormone variants
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
EP0939804B2 (en) 1996-10-25 2011-06-15 Human Genome Sciences, Inc. NEUTROKINE alpha
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
JP4450870B2 (en) 1997-01-28 2010-04-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Binding to death domain containing receptor 4 (DR4: death receptor 4), a member of the TNF-receptor superfamily and TRAIL
AU740207B2 (en) 1997-02-06 2001-11-01 Novozymes A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
CN1184315C (en) 1997-03-17 2005-01-12 人类基因组科学公司 Death domain containing receptor 5
AU7126498A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
EP0975754B2 (en) 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin binding proteins and their receptors
JP2001511653A (en) 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Apo-2 receptor
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
AU751898B2 (en) 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
AU8784498A (en) 1997-08-15 1999-03-08 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
ATE443761T1 (en) 1997-08-26 2009-10-15 Genentech Inc RTD RECEPTOR
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
US6740739B1 (en) 1998-01-15 2004-05-25 Genentech, Inc. Substitutional variants of APO-2 ligand
CA2318405C (en) 1998-01-26 2014-01-07 Genentech, Inc. Antibodies to death receptor 4(dr4) and uses thereof
PT1192185E (en) 1999-06-09 2006-11-30 Genentech Inc Apo-2l receptor agonist and cpt-11 synergism
US6318934B1 (en) * 1999-06-24 2001-11-20 Anchor Wall Systems, Inc. Segmental retaining wall system
CA2377585A1 (en) * 1999-06-28 2001-01-04 Genentech, Inc. Methods for making apo-2 ligand using divalent metal ions
DK1303293T3 (en) 2000-07-27 2009-03-30 Genentech Inc Sequential administration of CPT-11 and APO-2L polypeptide
EP1501866A4 (en) * 2001-10-02 2006-02-08 Genentech Inc Apo-2 ligand variants and uses thereof

Similar Documents

Publication Publication Date Title
JP2010065037A5 (en)
JP2010227108A5 (en)
JP2010088434A5 (en)
JP2011136981A5 (en)
JP2009268467A5 (en)
JP2011155981A5 (en)
JP2020022459A5 (en)
JP2013510581A5 (en)
JP2010532978A5 (en)
JP2012070736A5 (en)
JP2010501534A5 (en)
JP2011134884A5 (en)
JP2011511933A5 (en)
JP2007045829A5 (en)
JP2012115277A5 (en)
JP2010519252A5 (en)
JP2009504138A5 (en)
JP2007510403A5 (en)
JP2007175057A5 (en)
JP2011087580A5 (en)
JP2007508034A5 (en)
JP2013507132A5 (en)
JP2006006329A5 (en)
JP2016527891A5 (en)
JP2014028813A5 (en)